These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25020100)

  • 21. Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.
    Mukherjee S
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):1-2. PubMed ID: 27865911
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
    Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
    Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse.
    Franke GN; Lückemeier P; Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):1-7. PubMed ID: 33191169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
    Gergis U; Wissa U
    Curr Hematol Malig Rep; 2010 Jan; 5(1):1-8. PubMed ID: 20425390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.
    Oshikawa G; Yoshioka K; Takahashi Y; Shingai N; Ikegawa S; Kobayashil T; Doki N; Kakihana K; Ohashi K; Sakamaki H
    Pathol Oncol Res; 2015 Sep; 21(4):1037-43. PubMed ID: 25837848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
    Carella AM
    Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976
    [No Abstract]   [Full Text] [Related]  

  • 27. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.
    Aoki K; Ishikawa T; Ishiyama K; Aoki J; Itonaga H; Fukuda T; Kakihana K; Uchida N; Ueda Y; Eto T; Mori T; Kondo T; Iwato K; Morishima Y; Tanaka J; Atsuta Y; Miyazaki Y;
    Br J Haematol; 2015 Feb; 168(3):463-6. PubMed ID: 25228239
    [No Abstract]   [Full Text] [Related]  

  • 29. Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.
    Gerds AT; Deeg HJ
    Curr Opin Hematol; 2012 Mar; 19(2):71-5. PubMed ID: 22227527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of higher risk myelodysplastic syndromes].
    Usuki K
    Rinsho Ketsueki; 2019; 60(9):1131-1139. PubMed ID: 31597836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Inoue A; Kawakami C; Takitani K; Tamai H
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Principles and overview of allogeneic hematopoietic stem cell transplantation.
    Giralt S; Bishop MR
    Cancer Treat Res; 2009; 144():1-21. PubMed ID: 19779888
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes.
    Sekeres MA
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):346-350. PubMed ID: 30466745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.
    Field T; Perkins J; Huang Y; Kharfan-Dabaja MA; Alsina M; Ayala E; Fernandez HF; Janssen W; Lancet J; Perez L; Sullivan D; List A; Anasetti C
    Bone Marrow Transplant; 2010 Feb; 45(2):255-60. PubMed ID: 19543327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J
    Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
    Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Kim Y; Kim IH; Kim HJ; Park S; Lee KH; Kim SJ; Lee JH; Kim DY; Yoon SS; Kim YK; Jang JH; Park SY; Ahn JS; Cheong CW; Lee JH; Cheong JW;
    Int J Hematol; 2014; 99(5):635-43. PubMed ID: 24648120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.